Effective Sjögren’s management demands a strict separation between symptomatic relief for sicca and immunosuppression for ...
Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction ...
OSN Cornea/External Disease Board Member Eric D. Donnenfeld, MD, and a panel of experts examined a series of unusual ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback